

## Percutaneous Valvular and Structural Heart Disease Interventions. 2024 Core Curriculum of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardiovascular Surgery Working Group (WG CVS) of the European Society of Cardiology

Rui Campante Teles<sup>1\*</sup>, MD, PhD; Eric Van Belle<sup>2</sup>, MD, PhD; Radoslaw Parma<sup>3</sup>, MD, PhD; Giuseppe Tarantini<sup>4</sup>, MD, PhD; Nicolas Van Mieghem<sup>5</sup>, MD, PhD; Darren Mylotte<sup>6</sup>, MD, PhD; Joana Delgado Silva<sup>7</sup>, MD, PhD; Stephen O'Connor<sup>8</sup>, MD; Lars Sondegaard<sup>9</sup>, MD, PhD; Andre Luz<sup>10</sup>, MD, PhD; Ignacio Jesus Amat-Santos<sup>11</sup>, MD, PhD; Dabit Arzamendi<sup>12</sup>, MD, PhD; Daniel Blackman<sup>13</sup>, MD; Ole De Backer<sup>9</sup>, MD, PhD; Vijay Kunadian<sup>14</sup>, MD, PhD; Gill Louise Buchanan<sup>15</sup>, MD; Phil MacCarthy<sup>16</sup>, MD; Philipp Lurz<sup>17</sup>, MD, PhD; Christopher Naber<sup>18</sup>, MD, PhD; Alaide Chieffo<sup>19</sup>, MD, PhD; Valeria Paradies<sup>20</sup>, MD, PhD; Martine Gilard<sup>21</sup>, MD, PhD; Flavien Vincent<sup>2</sup>, MD; Chiara Fraccaro<sup>4</sup>, MD, PhD; Julinda Mehilli<sup>22</sup>, MD; Cristina Giannini<sup>23</sup>, MD; Bruno Silva<sup>24</sup>, MD; Petra Poliacikova<sup>25</sup>, MD, PhD; Nicole Karam<sup>26</sup>, MD, PhD; Verena Veulemans<sup>27</sup>, MD, PhD; Holger Thiele<sup>28</sup>, MD, PhD; Thomas Pilgrim<sup>29</sup>, MD, MSc; Marleen van Wely<sup>30</sup>, MD; Stefan James<sup>31</sup>, MD, PhD; Michael Rahbek Schmidt<sup>32</sup>, MD, PhD; Anselm Uebing<sup>33</sup>, MD, PhD; Andreas Rück<sup>34</sup>, MD, PhD; Alexander Ghanem<sup>35</sup>, MD, PhD; Ziyad Ghazzal<sup>36</sup>, MD, PhD; Francis R. Joshi<sup>9,37</sup>, MD, PhD; Luca Favero<sup>38</sup>, MD; Rencus Hermanides<sup>39</sup>, MD, PhD; Vlasis Ninios<sup>40</sup>, MD; Luca Nai Fovino<sup>4</sup>, MD, PhD; Rutger-Jan Nuis<sup>5</sup>, MD, PhD; Pierre Deharo<sup>41</sup>, MD, PhD; Petr Kala<sup>42</sup>, MD, PhD; Gabby Elbaz-Greener<sup>43</sup>, MD; Didier Tchéché<sup>44</sup>, MD; Eustachio Agricola<sup>45</sup>, MD, PhD; Matthias Thielmann<sup>46</sup>, MD, PhD; Erwan Donal<sup>47</sup>, MD, PhD; Nikolaos Bonaros<sup>48</sup>, MD, PhD; Steven Droogmans<sup>49</sup>, MD, PhD; Martin Czerny<sup>50</sup>, MD, PhD; Andreas Baumbach<sup>51</sup>, MD, PhD; Emanuele Barbato<sup>52</sup>, MD, PhD; Dariusz Dudek<sup>53,54</sup>, MD, PhD; in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardiovascular Surgery Working Group (WG CVS) of the European Society of Cardiology

R.C. Teles, E. Van Belle, R. Parma, G. Tarantini, N. Van Mieghem, E. Barbato, and D. Dudek contributed equally to this manuscript.

\*Corresponding author: Hospital de Santa Cruz, CHLO, Carnaxide and Comprehensive Health Research Center (CHRC), Nova Medical School, Avenida Professor Reinaldo dos Santos, 2790-134, Carnaxide, Lisbon, Portugal. E-mail: rcteles@outlook.com

### ABSTRACT

The percutaneous treatment of structural, valvular, and non-valvular heart disease (SHD) is rapidly evolving. The Core Curriculum (CC) proposed by the EAPCI describes the knowledge, skills, and attitudes that define competency levels required by newly trained SHD interventional cardiologists (IC) and provides guidance for training centres. SHD ICs are cardiologists who have received complete interventional cardiology training. They are multidisciplinary team specialists who manage adult SHD patients from diagnosis to follow-up and perform percutaneous procedures in this area. They are competent in interpreting advanced imaging techniques and master planning software. The SHD ICs are expected to be proficient in the aortic, mitral, and tricuspid areas. They may have selective skills in either the aortic area or mitral/tricuspid areas. In this case, they must still have common transversal competencies in the aortic, mitral, and tricuspid areas. Additional SHD domain competencies are optional. Completing dedicated SHD training, aiming for full aortic, mitral, and tricuspid competencies, requires at least 18 months. For full training in the aortic area, with basic competencies in mitral/tricuspid areas, the training can be reduced to 1 year. The same is true for training in the mitral/tricuspid area, with competencies in the aortic area. The SHD IC CC promotes excellence and homogeneous training across Europe and is the cornerstone of future certifications and patient protection. It may be a reference for future CC for national associations and other SHD specialities, including imaging and cardiac surgery.

**KEYWORDS:** aortic stenosis; atrial fibrillation; hypertrophic cardiomyopathy; imaging modalities; mitral regurgitation; training and education

The treatment of structural, valvular, and non-valvular heart disease (SHD) has been revolutionised by the emergence and development of percutaneous techniques. Percutaneous treatment of adult SHD is now a mature field supported by robust scientific evidence developed in recent decades and has been associated with significant benefits for both individuals and populations. While it is expected by both regulation authorities and patients that physicians will have had guidance for individual training (cardiologists, imaging cardiologists, cardiac surgeons, and first use of interventional cardiologist) in managing patients suffering from SHD, such recommendations are still lacking. The current Core Curriculum (CC) for percutaneous SHD interventions has been designed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) as the first key step to filling this gap in interventional cardiology. This innovative document has been prepared in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardiovascular Surgery Working Group (WG CVS) of the European Society of Cardiology (ESC). It will stimulate future Core Curricula in other SHD specialities where EAPCI is available to offer support and expects to collaborate, including imaging and cardiac surgery.

This curriculum was organised to follow and complement the Core Curriculum for Percutaneous Cardiovascular Interventions (2020) by the EAPCI Training and Certification Committee (TCC)<sup>1</sup>.

## Introduction

The present SHD CC aims to support the educational requirements of an updated European consensus. It defines and standardises competency levels required for percutaneous SHD interventions to treat patients with heart failure and cardiac symptoms related to valve disease or to prevent complications of thromboembolic diseases (Figure 1).

## Methodology

The writing task force included members with substantial expertise in different aspects of SHD percutaneous interventions nominated by EAPCI. Detailed data on this document's preparation process are found in the "2023 EAPCI Core Curriculum for Percutaneous Structural Heart Disease Interventions Extended Version" and are available upon request to the corresponding authors (Figure 2).

The 2023 EAPCI Core Curriculum for Percutaneous Structural Heart Disease Interventions Extended Version includes a comprehensive description of the specific components in 5 areas, organised into 114 chapters and subchapters. Each section includes statements on the objectives and is further subdivided into the required objectives, knowledge, skills, behaviours, ESC topic list, essential reading, and attitudes.

This manuscript aims to be a reference for future iterations that will occur under the auspices of the EAPCI (Central illustration).

## EAPCI Core Curriculum for Percutaneous Structural Heart Disease Interventions

### THE CLINICAL FIELD OF PERCUTANEOUS STRUCTURAL HEART DISEASE INTERVENTIONS

A solid background in coronary interventions, peripheral artery disease, and management of any procedural complications is needed, requiring a level of competence in interventional cardiology that is equal to or above the EAPCI Interventional Cardiology Core Curriculum 2020<sup>1-5</sup>.

The SHD CC differentiates between an "SHD IC" and a "Domain expert": the first chooses a comprehensive training in the Aortic (AOR) and/or Mitral/Tricuspid (MTC) modules. The latter is an IC whose differentiation is limited to particular areas: aortic, mitral, tricuspid, paravalvular regurgitation, septal ablation, adult congenital heart disease, ventricular septal defects, atrial septal defects, patent foramen ovale, left atrial appendage occlusions or pulmonary thromboembolism (Figure 3).

### GENERAL ASPECTS OF TRAINING IN PERCUTANEOUS SHD INTERVENTIONS

The candidates should be cardiologists licensed to practice IC in their country of training. A candidate should have completed a minimum of four years of training in general cardiology and two years of full-time training in IC. As part of the training in interventional cardiology, it is assumed that the IC has achieved all Level IV and Level V competencies described in the EAPCI IC CC<sup>1</sup>.

The trainee should have had exposure to an appropriate mix of aortic and mitral/tricuspid as well as acute and elective cardiac care, including mandatory, strongly recommended or recommended elements, as described below in Figure 4<sup>6-9</sup>.

### LEARNING OBJECTIVES


The trainee's education should include the competency domains of interventional cardiology: knowledge, skills, and attitudes which are defined below and should be reinforced during ongoing training. This section describes the definition of EAPCI levels of competence (LoC) recommendations for procedural or non-procedural skills. Their ascending order is summarised in Figure 5.

### REQUIREMENTS FOR TRAINING INSTITUTIONS, TRAINEES, AND TRAINERS


A percutaneous SHD training centre is an institution or healthcare network that performs SHD procedures and provides a structured training program for certified

## Abbreviations

<b>CC</b>	Core Curriculum	<b>SDAIC</b>	Scientific Documents and Initiatives Committee
<b>EACVI</b>	European Association of Cardiovascular Imaging	<b>SHD</b>	structural, valvular, and non-valvular heart disease
<b>EAPCI</b>	European Association of Percutaneous Cardiovascular Interventions	<b>TCC</b>	Training and Certification Committee
<b>IC</b>	interventional cardiologists/cardiology	<b>TF</b>	Task Force
<b>LoC</b>	levels of competence	<b>WG CVS</b>	Cardiovascular Surgery Working Group




**Figure 1.** The spectrum of cardiology areas treated by percutaneous structural heart disease interventions: valvular (aortic valve, mitral valve, tricuspid valves, paravalvular regurgitation) and non-valvular (hypertrophic obstructive cardiomyopathy septal ablation, ventricular septal defect, atrial septal defect, adult congenital heart disease, patent foramen ovale, left atrial appendage occlusion and pulmonary thromboembolism). These interventions can be used separately – or combined – to treat patients with thromboembolic diseases or heart failure. The colour code is consistent with the prevailing percutaneous treatment route, arterial (red), venous (blue) or mixed (red/blue). ACHD: adult congenital heart disease; ASD: atrial septal defect; HOCM: hypertrophic obstructive cardiomyopathy; LAAO: left atrial appendage occlusion; PFO: patent foramen ovale; PTE: pulmonary thromboembolism; PVL: paravalvular regurgitation; VSD: ventricular septal defect




**Figure 2.** Methodology of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Training and Certification Committee (TCC) Task Force (TF): the writing TF included three coordinating authors, a Nuclear Task Force (NTF) of 13 lead authors & group coordinators, and an Extended Task Force of 34 members, including the European Association of Cardiovascular Imaging (EACVI) and the Cardiovascular Surgery Working Group (WG CVS) of the European Society of Cardiology. The document was blindly revised by the EAPCI Scientific Documents and Initiatives Committee (SDAIC) and concluded after revision by the NTF and EAPCI Board. This version was circulated, revised, and approved by all authors. Finally, the Clinical Practice Guidelines (CPG) Committee formally approved the final version.

## The EAPCI Structural Heart Disease Training and Certification Pathway.



Rui Campante Teles *et al.* • *EuroIntervention* 2024;20:1370-1379 • DOI: 10.4244/EIJ-D-23-00983

Starting with a general cardiology degree, the interventional cardiologist training follows the EAPCI Interventional Cardiology (IC) Core Curriculum to acquire the EAPCI Interventional Cardiology Certification. Sequentially, the same training path follows the EAPCI Core Curriculum for Percutaneous Structural Heart Disease (SHD) Interventions to acquire the SHD Certification. An overlap between IC and SHD-IC certifications is accepted, allowing the IC to be certified 30 months after starting the IC Certification. Within the SHD Certification, the same principle is envisaged. While a comprehensive aortic/mitral/tricuspid is recommended, further dedicated training using the aortic or the mitral/tricuspid module is also possible, allowing SHD training to be completed in 1 year. The additional domains can be acquired in parallel when conditions permit. ACHD: adult congenital heart disease; ASD: atrial septal defect; EAPCI: European Association of Percutaneous Cardiovascular Interventions; LAAO: left atrial appendage occlusion; PFO: patent foramen ovale; PTE: pulmonary thromboembolism; PVL: paravalvular regurgitation; VSD: ventricular septal defect



**Figure 3.** The EAPCI Core Curriculum for Percutaneous SHD Interventions Training plan, modules, and domains: after the cardiology degree (minimum of 4 years of training) and interventional cardiologist (IC) certification (2 years) the trainee can engage in the comprehensive training module, the aortic/mitral/tricuspid (AoMTC), or choose between the aortic (AOR) and mitral/tricuspid (MTC) modules, respectively (red or light blue background, respectively). These modules are complementary, since each trainee involved in one module should still acquire minimal expertise from the other one. The recommended minimum duration of each of the two dedicated SHD IC training modules should be one year of training in SHD IC for each one of these areas, or 18 months when both are acquired in combination (AoMTC). In addition, as part of each module, the trainee will also have to acquire basic expertise in other specific SHD areas where full expertise can be acquired outside (or on top) of each SHD module (Figure 2) (dark blue or magenta backgrounds, that are related, respectively, with prevailing heart failure or thromboembolic disease). This optional “Domain expertise” recognition is designed to acknowledge the differentiation in any particular area included in the EAPCI SHD IC CC, without the requirement for transversal competencies as above: aortic intervention, mitral and tricuspid intervention, paravalvular regurgitation (PVL), septal ablation (HOCM), adult congenital heart disease (ACHD), ventricular septal defect (VSD), atrial septal defect (ASD), patent foramen ovale (PFO), left atrial appendage occlusion (LAAO) and pulmonary thromboembolism (PTE). Within the SHD Certification, practice overlap is possible to allow training in the Aortic, Mitral/Tricuspid modules, and any other domain can be acquired in parallel when conditions permit. The colour code is consistent with the prevailing disease: thromboembolic (magenta) or heart failure (red or blue background), and the competencies are delimited by different lines according to the usual percutaneous treatment route: arterial (red), venous (blue) or mixed (red/blue). SHD: structural heart disease

interventional cardiologists aiming to achieve the required EAPCI SHD CC LoC in a favourable environment.

The technical portfolio, organisation, referral network, volume and performance of the SHD training centre define the extent and quality of training in SHD<sup>10</sup>. The institution and affiliates must comply with the requirements and recommendations of their national regulatory bodies first and follow the ESC recommendations and Heart Valve Centres

concept, second<sup>11</sup>. An SHD training centre should have an established clinical, research and SHD training programme<sup>12-20</sup>.


Trainers should be recognised IC specialists, trained and certified in SHD (where available), and actively involved in the clinical and research activities of the local Heart Team. Their number should always match or exceed the number of trainees. The LoCs that a trainee needs to achieve at the end of his training period are summarised in **Figure 6**. A more




AREA OF TRAINING	GENERAL ASPECTS OF TRAINING	REQUIREMENT
SUPERVISOR & MENTOR REQUIREMENTS	> 5 years dedicated to percutaneous cardiovascular interventions	(M)
CONTINUOUS MEDICAL EDUCATION	Structured learning under supervision	(M)
OUTPATIENT CLINIC	Diagnostic, pre- and postprocedural assessment	(M)
MULTIMODALITY IMAGING FOR CLINICAL EVALUATION	Comprehensive analysis of echocardiography, MSCT and CMR imaging	(M)
HEART TEAM	Active participation in regular meetings	(M)
CARDIAC SURGERY OR	Exposure to open heart procedures	(R)
MAIN STRUCTURAL INTERVENTIONS	Main exposure to aortic and/or to mitral/tricuspid areas (AOR or MTC or AoMTC modules)	(M)
OTHER STRUCTURAL INTERVENTIONS	Exposure to other structural domains	(R+)
PROCEDURAL IMAGING GUIDANCE	Imaging-based procedural planning software and interventional guidance	(M)
LARGE VASCULAR ACCESS	All aspects of management	(M)
PROCEDURAL SKILLS	Progress from cases with direct supervision to independent operator status (AORTIC or MITRAL module)	(M)
RESEARCH	Participation in research & critical appraisal of evidence	(R)
EVALUATION	Regular & formal LoC progress assessment and clinical audit program	(M)

(M) Mandatory      (R+) Strongly recommended      (R) Recommended

**Figure 4.** Summary of the structured requirements for percutaneous training programmes in structural heart disease. AOR: aortic; CMR: cardiac magnetic resonance; LoC: level of competence; MSCT: multislice computed tomography; MTC: mitral/tricuspid; OR: operating room



**Figure 5.** Description of levels of competence (LoC) for non-procedural or procedural skills (adapted from *Entrustable Professional Activities*).



**Figure 6.** Condensed comparison of the level of competence (LoC) for non-procedural (\*) and procedural interventional cardiology skills in the AOR or MTC modules of the SHD IC (from I/1 to V/5). The AoMTC training requires, for any competence, the highest LoC of either AOR or MTC and is not presented to prevent confusion. The optional “Domain expert” recognition demands all theoretical requirements and a minimum LoC IV in all the domains of interventional cardiology, which are defined in their chapter or subchapter: aortic, mitral/tricuspid, septal ablation (HOCM), paravalvular leak (PVL), ventricular septal defect (VSD), atrial septal defect (ASD), adult congenital heart disease (ACHD), patent foramen ovale (PFO), left atrial appendage occlusion (LAAO) and pulmonary thromboembolism (PTE). HOCM: hypertrophic obstructive cardiomyopathy; TAVI: transcatheter aortic valve intervention; THV: transcatheter heart valve; TMVR: transcatheter mitral valve replacement; TMVI: transcatheter mitral valve intervention; TV: transcatheter valves

detailed description of each area of training is provided in the extended version of the document.

([https://www.escardio.org/Sub-specialty-communities/European-Association-of-Percutaneous-Cardiovascular-Interventions-\(EAPCI\)](https://www.escardio.org/Sub-specialty-communities/European-Association-of-Percutaneous-Cardiovascular-Interventions-(EAPCI))).

## Conclusions

The Percutaneous Valvular and Structural Heart Disease Interventions Core Curriculum of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) provides guidance for training centres and trainees.

It describes the knowledge, skills, and attitudes that define competency levels required from newly trained interventional cardiologists performing structural heart disease interventions. They should train within multidisciplinary teams, managing adult patients from diagnosis to follow-up, developing selective skills in either aortic and/or mitral/tricuspid areas. Their education may be complemented by competencies in other domains such as adult congenital heart disease, left atrial appendage occlusion, pulmonary thromboembolism, paravalvular regurgitation, septal ablation or septal defects.

The Core Curriculum promotes excellence and universal training in ESC countries, forming the cornerstone of future certifications for patient protection.

## Authors' affiliations

1. Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Carnaxide and Comprehensive Health Research Center (CHRC), Nova Medical School, Lisbon, Portugal;
2. CHU Lille, Institut Coeur Poumon, Cardiologie, Université de Lille, France;
3. Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland;
4. Interventional Cardiology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy;
5. Erasmus Mc, Interventional Cardiology, Rotterdam, the Netherlands;
6. Department of Cardiology, University Hospital and National University of Ireland, Galway, Ireland;
7. Cardiovascular Intervention Unit, Cardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal;
8. St James's Hospital, Cardiology Unit, Dublin, Ireland;
9. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;
10. Centro Hospitalar Universitário do Porto, Porto, Portugal;
11. Hospital Clinico Universitario, Cardiology Department, Valladolid, Spain;
12. Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain;
13. Leeds Teaching Hospitals, Leeds, United Kingdom;
14. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;
15. North Cumbria Integrated Care NHS Foundation Trust, Department of Cardiology Cumberland Infirmary, Carlisle, United Kingdom;
16. King's College Hospital, London, United Kingdom;
17. Department of Cardiology, Universitätsmedizin Mainz, Mainz, Germany;
18. Facharztpraxis Baldeney - Kardiologie und Innere Medizin, Essen, Germany;
19. Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy, and Vita-Salute San Raffaele University, Milan, Italy;
20. Maasstad Hospital, Rotterdam, the Netherlands;
21. CHU La Cavale Blanche, Department Of Cardiology, Brest, France;
22. Department of Cardiology, Pulmonology and Intensive

- Medicine, Hospital Landshut-Achdorf, Landshut, Germany;
23. SD Emodinamica, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy;
24. Cardiology Department, Hospital Central do Funchal, Madeira, Portugal;
25. Central Slovakia Institute of Cardiovascular diseases, Banska Bystrica, Slovakia;
26. European Hospital Georges Pompidou, Cardiology Department, Paris, France;
27. University Heart and Vascular Center Frankfurt, Germany;
28. Leipzig Heart Centre, Internal Medicine/Cardiology, University of Leipzig, Leipzig, Germany;
29. Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;
30. Radboud UMC, Department of Cardiology, Nijmegen, the Netherlands;
31. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden;
32. Adult Congenital Heart Disease Unit, Department of Cardiology, Rigshospitalet, Copenhagen, Denmark;
33. Department of Congenital and Paediatric Cardiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany and German Centre for Cardiovascular Research, Partner Site Kiel, Kiel, Germany;
34. Karolinska University Hospital, Department of Cardiology, Stockholm, Sweden;
35. Asklepios Klinik Nord - Heidberg, Hamburg, Germany;
36. American University of Beirut, Beirut, Lebanon;
37. Golden Jubilee National Hospital, Clydebank, United Kingdom;
38. Cardiovascular Department, Ca' Foncello Regional Hospital, Treviso, Italy;
39. Isala Heart centre, Isala Hospital, Department of Cardiology, Zwolle, the Netherlands;
40. Cardiology Department, Interbalkan European Medical Center, Thessaloniki, Greece;
41. Hopital de la Timone, Department of Cardiology, Marseille, France;
42. Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic and Department of Internal Medicine and Cardiology, Medical Faculty of Masaryk University, Brno, Czech Republic;
43. Hadassah Medical Center, Hebrew University, Jerusalem, Israel;
44. Clinique Pasteur, Groupe Cardiovasculaire Interventionnel, Toulouse, France;
45. Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy;
46. Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center Essen, University Duisburg-Essen, Essen, Germany;
47. Cardiology Department, Université de Rennes-1, CHU de Rennes, Rennes, France;
48. Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria;
49. UZ Brussel, Department of Cardiology, Jette, Belgium;
50. Clinic for Cardiovascular Surgery, University Heart Center Freiburg Bad Krozingen, Bad Krozingen, Germany and Faculty of Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany;
51. Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, United Kingdom;
52. Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy;
53. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland;
54. Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy

## Data availability statement

No new data were generated or analysed in support of this document.

## Acknowledgements

The Clinical Practice Guidelines (CPG) Committee from the European Society of Cardiology formally approved the document.



## Conflict of interest statement

E. Agricola has received speaker honoraria and compensation from GE HealthCare, outside the current topic. I.J. Amat-Santos has received speaker honoraria and advisory board compensation from Boston Scientific, Meril Life, Medtronic, and Abbott. A. Baumbach has received institutional research support from Biotronik; and honoraria from Faraday, Pi-Cardia and Meril Life. D. Blackman has acted as a consultant, advisory board member, and speaker for Abbott, Edwards Lifesciences, and Medtronic. N. Bonaros has received speaker honoraria from Edwards Lifesciences and Medtronic; as well as research grants from Edwards Lifesciences and Corcym. M. Czerny is consultant to Terumo Aortic, Medtronic, NEOS, and Endospa. O. De Backer has received research grants, speaker and consulting fees from Abbott, Boston Scientific, and Medtronic. P. Deharo has received honoraria from Boston Scientific, Abbott, Asahi, Medtronic and Novartis. P. Lurz has received institutional fees and research grants from Abbott, Edwards Lifesciences, and ReCor; honoraria from Edwards Lifesciences, Abbott, Innoventric, ReCor and Boehringer Ingelheim; and has stock options with Innoventric. R. Hermanides has received compensation from companies outside the current topic. S. James has received institutional research support from Edwards Lifesciences and Medtronic; and proctoring fees from Medtronic. F.R. Joshi has received honoraria and advisory board compensation from Boston Scientific; and travel support from Millbrook Medical. P. Kala declares that he has received consultant and speaker fees from Boston Scientific, Edwards Lifesciences, Sanofi, Novartis, and Servier; participated in advisory boards from Boston Scientific, Abbott, Novartis, and Servier; and received research support from Bayer, Novartis, and Amgen. N. Karam has received consultant fees from Abbott, Medtronic, Edwards Lifesciences, and Boston Scientific. A. Luz has received consultant fees from Abbott. J. Mehilli has received speaker honoraria and compensation from AstraZeneca, Boston Scientific, Daiichi Sankyo, and Shockwave. D. Mylotte has received research grants from Boston Scientific; and speaker honoraria/advisory board compensation from Medtronic, Microport, and Boston Scientific. R. Nuis has received research grant support from Vifor Pharma; and consulting fees from Edwards Lifesciences, Abbott, and Boston Scientific. V. Paradies declares research grants from Abbott to the institution; and speaker fees from Abbott and Boston Scientific. R. Parma has received speaker fees from Edwards Lifesciences. A. Rück declares institutional research and educational grants from Boston Scientific and Edwards Lifesciences; and personal speaker and consultancy fees from Boston Scientific, Abbott, Edwards Lifesciences, and Anteris. T. Pilgrim reports research, travel or educational grants to the institution without personal remuneration from Biotronik, Boston Scientific, and Edwards Lifesciences; and speaker fees and consultancy fees to the institution from Biotronik, Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, Biosensors, and Highlife. G. Tarantini has received speaker honoraria/advisory board compensation from Edwards Lifesciences, Boston Scientific, Medtronic, Abbott, Philips, and Microport. D. Tchéché is consultant for Abbott,

Boston Scientific, Edwards Lifesciences, and Medtronic. A. Uebing has received advisory board compensation from Medtronic. N. Van Mieghem has received research grant support from Abbott, Boston Scientific, Medtronic, AstraZeneca, and Daiichi Sankyo; and scientific advisory fees from Anteris, JenaValve, Amgen, Siemens, Pie Medical, Abbott, Boston Scientific, Medtronic, AstraZeneca, and Daiichi Sankyo. M. van Wely has received proctoring fees from Abbott; and speaker fees from Boston Scientific. V. Veulemans has received consulting fees, travel expenses, or study honoraria from Medtronic, Edwards Lifesciences, and Boston Scientific. The other authors have no conflicts of interest to declare.

## References

1. Van Belle E, Teles RC, Pyxaras SA, Kalpak O, Johnson TW, Barbash IM, De Luca G, Kostov J, Parma R, Vincent F, Brugaletta S, Debry N, Toth GG, Ghazzal Z, Deharo P, Milasinovic D, Kaspar K, Saia F, Mauri Ferre J, Kammler J, Muir DF, O'Connor S, Mehilli J, Thiele H, Weilenmann D, Witt N, Joshi F, Kharbada RK, Piroth Z, Wojakowski W, Geppert A, Di Gioia G, Pires-Morais G, Petronio AS, Estevez-Loureiro R, Ruzsa Z, Kefer J, Kunadian V, Van Mieghem R, Windecker S, Baumbach A, Haude M, Dudek D. EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020): Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology. *EuroIntervention*. 2021;17:23-31.
2. Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletta F, Lancellotti P, Mahmoud-Elsayed H, Marsan NA, Maurovich-Hovart P, Monaghan M, Ribeiro J, Sade LE, Swaans M, Von Bardeleben RS, Wunderlich N, Zamorano JL, Popescu BA, Cosyns B, Edvardsen T; Reviewers: This document was reviewed by members of the 2018-2020 EACVI Scientific Documents Committee. The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2021;22:471-9.
3. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, Bueno H, Lettino M, Price S, Valgimigli M, Jeppsson A. Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. *Eur Heart J Acute Cardiovasc Care*. 2021;10:83-93.
4. Parma R, Zembala MO, Dąbrowski M, Jagielak D, Witkowski A, Suwalski P, Dudek D, Olszówka P, Wojakowski W, Przybylski R, Gil R, Kuśmierczyk M, Lesiak M, Sadowski J, Dobrzycki S, Ochala A, Hoffman P, Kapelak B, Kaźmierczak J, Jasiński M, Stępińska J, Szymański P, Hryniewiecki T, Kochman J, Grygier M, Zembala M, Legutko J, Różański J. Transcatheter aortic valve implantation. Expert Consensus of the Association of Cardiovascular Interventions of the Polish Cardiac Society and the Polish Society of Cardio-Thoracic Surgeons, approved by the Board of the Polish Cardiac Society.... *Kardiologia Pol*. 2017;75:937-64.
5. Loureiro-Ga M, Veiga C, Fdez-Manin G, Jimenez VA, Juan-Salvadores P, Busto L, Baz JA, Iñiguez A. Predicting TAVI paravalvular regurgitation outcomes based on numerical simulation of the aortic annulus eccentricity and perivalvular areas. *Comput Methods Biomech Biomed Engin*. 2021;24:1629-37.
6. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739-91.
7. Lorenzoni V, Barbieri G, Saia F, Meucci F, Martinelli GL, Cerillo AG, Berti S, Candolfi P, Turchetti G. The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups. *Eur J Health Econ*. 2021;22:1349-63.

8. Pongiglione B, Torbica A, Blommestein H, de Groot S, Ciani O, Walker S, Dams F, Blankart R, Mollenkamp M, Kovács S, Tarricone R, Drummond M. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. *Int J Technol Assess Health Care*. 2021;37:e62.
9. Saad AM, Kassis N, Isogai T, Gad MM, Ahuja KR, Abdelfattah O, Shekhar S, Farwati M, Yun JJ, Krishnaswamy A, Svensson LG, Kapadia S. Trends in Outcomes of Transcatheter and Surgical Aortic Valve Replacement in the United States (2012-2017). *Am J Cardiol*. 2021;141:79-85.
10. VARC-3 WRITING COMMITTEE; Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. *Eur Heart J*. 2021;42:1825-57.
11. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *EuroIntervention*. 2022;17:e1126-96.
12. Bavaria JE, Tommaso CL, Brindis RG, Carroll JD, Deeb GM, Feldman TE, Gleason TG, Horlick EM, Kavinsky CJ, Kumbhani DJ, Miller DC, Seals AA, Shahian DM, Shemin RJ, Sundt TM 3rd, Thourani VH. 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2019;73:340-74.
13. Flynn MR, Barrett C, Cosío FG, Gitt AK, Wallentin L, Kearney P, Lonergan M, Shelley E, Simoons ML. The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. *Eur Heart J*. 2005;26:308-13.
14. Carlhed R, Bojestig M, Peterson A, Aberg C, Garmo H, Lindahl B; Quality Improvement in Coronary Care Study Group. Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative. *Circ Cardiovasc Qual Outcomes*. 2009;2:458-64.
15. Bekerredjian R, Szabo G, Balaban Ü, Bleiziffer S, Bauer T, Ensminger S, Frerker C, Herrmann E, Beyersdorf F, Hamm C, Beckmann A, Möllmann H, Karck M, Katus HA, Walther T. Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY). *Eur Heart J*. 2019;40:1323-30.
16. Van Belle E, Vincent F, Labreuche J, Auffret V, Debry N, Lefèvre T, Eltchaninoff H, Manigold T, Gilard M, Verhoye JP, Himbert D, Koning R, Collet JP, Leprince P, Teiger E, Duhamel A, Cosenza A, Schurtz G, Porouchani S, Lattuca B, Robin E, Coisne A, Modine T, Richardson M, Joly P, Rioufol G, Ghostine S, Bar O, Amabile N, Champagnac D, Ohlmann P, Meneveau N, Lhermusier T, Leroux L, Leclercq F, Gandet T, Pinaud F, Cuisset T, Motreff P, Souteyrand G, Iung B, Folliguet T, Commeau P, Cayla G, Bayet G, Darremont O, Spaulding C, Le Breton H, Delhay C. Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison From the FRANCE-TAVI Registry. *Circulation*. 2020;141:243-59.
17. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J*. 2012;33:2403-18.
18. Ocagli H, Lorenzoni G, Lanera C, Schiavo A, D'Angelo L, Liberti AD, Besola L, Cibin G, Martinato M, Azzolina D, D'Onofrio A, Tarantini G, Gerosa G, Cabianca E, Gregori D. Monitoring Patients Reported Outcomes after Valve Replacement Using Wearable Devices: Insights on Feasibility and Capability Study: Feasibility Results. *Int J Environ Res Public Health*. 2021;18:7171.
19. Kingsley C, Patel S. Patient-reported outcome measures and patient-reported experience measures. *BJA Educ*. 2017;17:137-44.
20. Tanner FC, Brooks N, Fox KF, Gonçalves L, Kearney P, Michalis L, Pasquet A, Price S, Bonnefoy E, Westwood M, Plummer C, Kirchhof P; ESC Scientific Document Group. ESC Core Curriculum for the Cardiologist. *Eur Heart J*. 2020;41:3605-92.